Abdul Mutlib, Ph.D.
Dr. Abdul Mutlib is the Chief Executive Officer at Frontage Laboratories, Inc. Before this, he was the Global Head of DMPK/Preclinical Services and led operations for these services. Prior to joining Frontage in 2010, he held director-level roles within drug metabolism teams at Wyeth and Pfizer. Earlier in his career, he held scientific positions on the drug metabolism teams at Hoechst-Roussel and DuPont-Merck. With more than 20 years of experience in drug metabolism and analytical chemistry, Dr. Mutlib’s research includes the application of various analytical techniques and stable isotope labeled compounds in elucidating structures of metabolites and metabolic pathways; mass spectrometry; qualitative and quantitative NMR; metabolism-mediated toxicities; reactive metabolites; phase II metabolism; drug-drug interactions; and toxicogenomics. He has published more than sixty papers in peer-reviewed journals.
Dr. Mutlib earned a bachelor’s degree in pharmacy and a doctor of philosophy degree in pharmaceutical chemistry from the University of Sydney in Australia. He completed post-doctoral fellowships from the Universities of Washington and British Columbia.
